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ABSTRACT  
Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with 50% risk 
of metastases at initial diagnosis or at follow-up. An inactivation of the tumor suppressor gene 
VHL is present in more than 70% of sporadic cases by two of three different mechanisms: 
locus deletion, gene mutation or promoter hypermethylation.  
Objective: To correlate the complete status of the VHL gene with clinical and pathological 
criteria.  
Design, Setting, and Participants: We retrospectively included 98 ccRCCs operated between 
2002 and 2005. VHL gene deletions (71/98, 72.4%), mutations (68/98, 69.4%) and promoter 
hypermethylations (13/98, 13.3%) were screened by gene copy analysis, gene sequencing and 
Methylation Specific-MLPA respectively.  
Outcome Measurements and Statistical Analysis: Relationships between VHL subgroups and 
the studied criteria were analyzed using χ2 and Student’s tests. Survival using log rank test 
and Kaplan Meier curves. 
Results and Limitations: Compared to ccRCCs with 2 events (66.3%), tumors with 0 or 1 
genetic event (33.6%) were associated with a higher nuclear grade 4 (p=0.02), metastases 
(p=0.04), sarcomatoid component (p=0.01), dense lymphocyte infiltrate (p=0.013) and to 
VEGF overexpression (>30%) (p=0.003), which was also an independent factor after 
multivariate analysis. Furthermore, wild type VHL tumors (no inactivating event, 11.2%) 
were associated with nodal involvement (p=0.019), and had a specific survival of 33 months 
compared to patients with ccRCCs having 1 or 2 VHL inactivating events (107 months) (p 
=0.016). The retrospective design with small number of wild type tumors was a limitation to 
this work. 
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Conclusions: This long term study (10-year clinical follow-up) confirms that ccRCCs with 
wild type VHL are highly aggressive tumors that need to be formerly identified. 
Patient Summary: Among activated VHL tumors, the wild type subgroup defines an 





Renal cell carcinoma accounts for 3% of incidental solid tumors, of whom 70% to 75% are 
clear cell renal cell carcinomas (ccRCC) which are highly vascularized tumors. VHL is a 
major tumor suppressor gene involved in renal carcinogenesis. Alterations englobing its locus 
on chromosome 3p25-p26 in ccRCCs have been first described in patients with Von Hippel 
Lindau disease but VHL gene abnormalities are also observed in 60% to 70% of sporadic 
ccRCCs [1-3]. These genetic alterations are specific of the clear cell subtype and are typically 
not associated with other histological subtypes of renal carcinoma [4].   
At a cellular level, VHL acts as a tumor-suppressor gene. Its protein, pVHL, is a 
multifunctional protein insuring variable regulatory functions such as remodeling extra 
cellular matrix and controlling the cell cycle. The function that has been most thoroughly 
studied is the stability regulation of hypoxia inductible factor (HIF). pVHL is a component of 
an E3 ubiquitin-ligase which targets proteins, including the transcription factor HIF, leading 
to their ubiquitination and degradation by proteasomes. The consequence of pVHL 
impairment is a stabilization and increased level of HIF, leading to the transcription of genes 
regulated by HIF such as vascular endothelial growth factor (VEGF) or carbonic anhydrase IX 
(CAIX) [5]. Consequently, VHL acts as one of the main triggers of the angiogenic processes in 
ccRCC. 
VHL gene impairments described in ccRCC necessarily involve biallelic alterations in tumor 
cells as both first and second “hits” must occur to be inactivated. These may reflect either 
mutations or deletions of the gene and/or hypermethylation of its promoter. One third of 
ccRCCs however exhibit no or a single allele alteration of VHL. Even if its key role is not 
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completely elucidated, the association between VHL alterations and ccRCC carcinogenesis is 
well admitted at an early stage.  
In this study, we aimed to perform a detailed analysis of the VHL status in a retrospective 
cohort of ccRCCs in correlation with pathological criteria and long term clinical outcomes. 
Our main goal was to seek differences in histological aspects depending on the complete VHL 
gene status. Our second objective was to verify if a given VHL group was associated with a 
worse prognosis, which was clinically relevant as the duration of our follow-up was a decade 
long.  
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MATERIALS AND METHODS 
Patients 
Patients operated for sporadic ccRCC in the Department of Urology at Rennes Hospital 
between 2002 and 2005 were retrospectively included. Care following surgery complied with 
standard recommendations for the given period, and patients’ clinical conditions were 
monitored by the ECOG scale [6]. The study protocol was approved by the local advisory 
board and informed consent was obtained from each patient.  
Tissue sample management 
All consecutive and histologically validated ccRCCs were analyzed. Immediately after 
macroscopic examination, small samples were collected from surgical specimens and stored 
at -80°C until DNA extraction, using QIAamp DNA minikit (Qiagen, Courtaboeuf, France). 
DNA quantity and quality were estimated by optical density (OD 260/280) measurement and 
0,8% agarose gel electrophoresis using standard protocols. 
Pathological analysis 
After fresh tissue sampling, surgical specimens were formalin-fixed. Paraffin sections were 
stained with hematoxylin and eosin-safran. The analyzed parameters were: tumor size, 
multifocality, nuclear grade, sarcomatoid pattern, tumor necrosis, granular component, 
lymphocyte infiltrate and microvessel invasion. Tumor stage was defined according to the 
latest International Union Against Cancer 2009 classification [7].  
Immunochemistry 
For each case, a representative slide of the tumor with the highest nuclear grade was selected. 
VEGFA (Anti-VEGFA, sc-152; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and CAIX 
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(Anti-CAIX, ab15086, Abcam, Cambridge, UK) expressions were assessed by 
immunohistochemistry. The cut-off for positive cases was 30% of tumor cells for VEGF and 
85% for CAIX as previously described [8-10]. Negative control was performed by omitting 
the primary antibody. Regarding tumor infiltrating lymphocytes, CD3 (anti-CD3, clone SP7, 
dilution 1/100; Thermo Scientific, Waltham, MA, USA) and CD20 (anti-CD20, clone L26, 
dilution 1/25; Dako, Glostrup, Denmark) expressions were assessed. The inflammatory extent 
was coded as 1 (sparse and rare lymphocytes) or 2 (marked dense lymphocytes or lymphoid 
nodules). The reactivity of antibodies was revealed with HRP-labeled polymer conjugated 
secondary antibodies using diaminobenzidine (Sigma-Aldrich, France). Tumor expressions 
were independently evaluated without knowledge of patient outcome or VHL gene status 
(NRL).  
VHL gene analysis 
The detection of VHL mutations was performed by sequencing in denaturing high 
performance liquid chromatography (DHPLC). We amplified two overlapping fragments for 
exon 1 (1A and 1B) and one fragment for each of exons 2 and 3, covering part of the VHL-
5’UTR, the entire coding sequence and exon-intron junctions (VHL Genbank accession 
AF010238) as previously described [11]. After purification, forward and reverse automatic 
sequencing was performed using BigDye Terminator v1.1 Cycling Sequencing kit on an ABI 
Prism 3100 Genetic Analyser (Applied Biosystems, Courtaboeuf, France). All mutations were 
confirmed in a second round of PCR and sequencing reactions. 
Multiplex Ligation–dependent Probe Amplification (MLPA) analysis was used to detect 
deletions or duplications of the VHL gene with the SALSA MLPA P016B VHL probe kit 
(MRC-Holland, Amsterdam, Netherlands), targeting the three VHL exons.  
 
 9 
After denaturation and probe hybridization, PCR was performed and fragments were 
separated by electrophoresis on an Applied 3130XL capillary sequencer and quantified using 
the GeneMarker version 1.6 software (SoftGenetics). For copy number detection, normal 
control DNA samples were included in each set of MLPA experiments. Interpretation was 
based on the comparison of peak heights between control DNA and the tumor sample. Cut-off 
levels for loss of relative copy number were set at 0.75.  
Methylation-Specific-MLPA (MS-MLPA) was used to detect CpG methylation in the VHL 
gene promotor [12]. The probe design containing a methylation-sensitive restriction site 
(HhaI) allowed detecting aberrant methylation of CpG-islands located in the promoter region 
of the VHL gene using the SALSA MS-MLPA ME001B Tumor suppressor-1 kit. 
Regarding tumor heterogeneity, we additionally performed VHL studies in 10 patients, in 
different tumor regions, revealing the same VHL status as initially described.  
Statistical analysis 
Chi2 and Student’s tests were performed to compare qualitative and quantitative parameters 
respectively between groups. Multivariate analysis was then performed. Cancer specific 
survival was compared by log rank test and represented with Kaplan Meier curves. All 
analyses were conducted by AP with the Stata 11.1 (College Station, TX) software and the p-
value significance was fixed at 0,05. 
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RESULTS  
Patients and histological parameters 
The analysis retrospectively included 98 patients. The median age at diagnosis was 64 years 
(40-84). Sixty nine patients (70%) had an ECOG performance status of 0. In 11 cases 
(11.2%), nodal invasion was present at diagnosis and 23 cases (23.5%) had metastases. With 
time, 26 patients (26.5%) developed metastases after initial diagnosis. Metastatic patients 
received diverse therapies including immunotherapies, tyrosine-kinase inhibitors, 
hormonotherapies, and classic chemotherapy. At a median follow-up of 64 months (0-139 
months), 44 (44.9%) subsequently died from their cancer and 51 (52%) patients suffered from 
disease progression. The mean tumor size was 7.3 cm +/- 3.4 cm with tumors ranging from 
1.5 to 18 cm. Population characteristics as well as pathological parameters are summarized in 
Table 1. 
Genetic and epigenetic VHL gene alteration  
All patients were negative for germ-line mutations. A VHL gene mutation was found in 68 
cases (69.4%). Mutations occurred in exons 1, 2 and 3 in 27 (27.6%), 27 (27.6%) and 14 
cases (14.3%) respectively. Stop, frameshift, missense, and splice site mutations were found 
in 10 (10.2%), 33 (33.7%), 19 (19.4%) and 6 (6.1%) cases respectively. VHL loss of 
heterozygosity and promoter methylation occurred in 71 (72.4%) and 13 cases (13.3%) 
respectively. At least one or more VHL abnormalities were found in 87 cases (88.8%). 
Tumors with 2 alterations of the VHL gene (n=65 cases, 66.3%) were termed inactivated for 
that gene (inVHL). Those with none or only one alteration (n=33, 33.7%) were grouped as 
activated VHL tumors (acVHL). These included tumors with no alteration of the VHL gene 
(n=11, 11,2%) that were termed wild type (wtVHL) (Figure 1). 
Association between VHL gene alterations and histological parameters  
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acVHL tumors presented an aggressive clinical and pathological profile compared to ccRCCs 
with inVHL. Fuhrman grade 4 (p=0.02), metastasis (p=0.04), sarcomatoid component 
(p=0.03), especially when estimated as ≥ 20% (p=0.0006), dense lymphocyte infiltrate 
(p=0.013) and overexpression of intratumoral VEGF (p=0.0001) were significantly associated 
with acVHL ccRCCs (Tables 1 and 2). The overexpression of VEGF remained significant 
after multivariate analysis (p= 0.004). Interestingly, lymph node metastases (p=0.019) was 
additionally associated with the subgroup of wtVHL. The expression of CAIX was not 
associated with any subgroup (mean expression: 88,9% for inVHL, 83% for acVHL and 
74,3% for wtVHL), even though the positive expression of VEGF in tumor cells was inversely 
correlated with the expression of CAIX (p=0.002, data not shown) (Figure 2). 
Relationship between VHL gene alterations and survival 
While no significant difference was observed concerning specific survival rates between 
acVHL and inVHL cases (p=0.078), the subgroup of wtVHL patients showed a separate 
evolution compared to both inVHL and patients with one VHL alteration (p=0.016), and 
separately compared to inVHL patients (p=0.009). The survival curves of the 3 subgroups 
(inVHL, acVHL with one alteration, and acVHL with no alteration-wtVHL) are illustrated in 
Figure 3. Patients with wild type VHL had the worse prognosis with a median specific 
survival of 33 months compared to patients with a VHL gene inactivation who had a median 
specific survival of 82 months (p=0.035).  
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DISCUSSION 
This is the first study to our knowledge, with a long term clinical follow-up of ten years that 
deals with histological differences between ccRCCs depending on their complete VHL status. 
It shows the presence of three subgroups of tumors with different phenotypes and clinical 
outcomes. Clear cell renal cell carcinoma is a highly vascularized tumor, and the major gene 
implicated in its carcinogenesis at an early stage is VHL, a tumor suppressor gene that 
requires at least two events, one on each allele to be inactivated, as VHL is not a 
haploinsufficient tumor-suppressor gene. Deletion of the VHL gene locus was the most 
frequent event, 72.4% in our series which is less than the 91% loss of the 3p region observed 
in a recent cancer genome study [13]. In this same study, mutations of the VHL gene were 
observed in 52% of cases and promoter hypermethylations in 7% of tumors. Theses events are 
reported in a variable percentage in the literature, between 34% and 71% for mutations 
[14,15], and between 5% and 19% for promoter hypermethylations [16,17]. We observed 
69.4% and 14.2% of these events respectively. As expected, mutations and promoter 
methylations were mutually exclusive as no case exhibited the two events simultaneously. 
Mutations of the exons 1 and 2 were more frequent than those of exon 3 and frameshift 
mutations were the most common types of mutational events. Tumors with 2 VHL hits 
(inVHL (2)) represented 66.3% of patients, which was more frequent than tumors with only 
one hit (acVHL (1), 22.4%) and even more frequent than tumors with no VHL event (wtVHL 
(0), 11.2%).  
VHL inactivation was associated with a better prognosis and this was illustrated by better 
survival rates, lower nuclear grade, less metastases, and less sarcomatoid component in this 
group of tumors than in acVHL tumors. Indeed, we observed that several factors were 
significantly associated with acVHL cases. In opposition to tumors with at least two 
alterations of the VHL gene, acVHL tumors were associated with higher nuclear 4 grade and 
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metastases. Sarcomatoid component was also more frequent in this group. This parameter is a 
major and well known poor prognostic factor [18], and our results are consistent with recent 
studies describing low HIF-1α expression (due to a functional pVHL protein: acVHL) in 
ccRCCs with a sarcomatoid component [19].  
Dense lymphocyte infiltrate was associated with acVHL tumors. In ccRCC, the intra-tumoral 
mononuclear infiltrate is associated with pejorative outcomes and higher nuclear grade [20-
22]. For instance, binding of programmed death ligand 1 (PD-L1) expressed by tumor cells to 
the co-stimulatory receptor on T regulatory cells, PD-1, promotes inactivation and apoptosis 
of activated tumor specific T lymphocytes, and blockade of PD-1 or its ligand PD-L1 by 
specific antibodies produce objective responses in some cancers including renal cell 
carcinomas [23-24]. This particularly dense lymphocyte infiltrate associated to acVHL tumors 
could be investigated looking for PD1-positive cells implicated in prognosis of ccRCCs and 
in PD1-based immunotherapy [25].  
Surprisingly, the overexpression of VEGF was also independently associated with acVHL 
tumors and inversely correlated to the overexpression of CAIX. Both CAIX and VEGF are 
VHL/HIF downstream targets. However, unlike CAIX, which is a surrogate indicator for 
VHL status, VEGF regulation is much more complex. These results support the theory of 
alternative oncogenic pathways in ccRCC leading to VEGF overexpression despite HIF 
degradation due to the presence of an activated VHL protein (acVHL). Tumors with no 
inactivation of VHL could use alternative pathways independent from VHL mechanisms and 
lead to VEGF overexpression promoting tumor angiogenesis. These alternative pathways [26-
30], that include the MAP kinase and the PI3K-AKT-mTOR pathways, may be potentially 
implicated in the resistance to targeted therapy by tyrosine kinase inhibitors.  
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Furthermore, the subgroup of wtVHL tumors was clearly of worse prognosis as demonstrated 
by significant poorer specific survival rates. In our study, clinical outcomes did not 
significantly differ between the first two groups (inVHL and acVHL with one event). 
However, the group of patients with wtVHL exhibited significant worse outcomes: 73% of 
wtVHL patients died from their cancer at the end of follow-up, compared to 45% of patients 
with one VHL alteration and 40% of patients with inVHL tumors.  
The limitations to this study, besides the small number of wild type cases, are the variation of 
treatment given to metastatic patients at the time before full market approval of protein-
tyrosine kinase inhibitors as a first-line drug; similarly to all studies realized on kidney cancer 
at that time. The other limitation is the high frequency of metastatic patients in the wild type 
group, disabling us from excluding metastatic patients from the analysis, and which does not 
allow a metastatic-independent evaluation of mortality. 
 
CONCLUSIONS 
This study shows the existence of three groups of ccRCCs depending on their VHL status. The 
wtVHL subgroup is a separate entity of worse prognosis. The wider perspective of this study 
is to increase these cases that represent only 10% of ccRCCs for a better molecular 
characterization and the study of wtVHL tumors in non-metastatic patients. Such an increase 
would enable us to dig further in what makes these tumors so specific and more aggressive, 
and in why VEGF remains at high levels of expression, despite a VHL protein that is intact. 
These tumors could be screened more thoroughly and studied as factors of resistance or 
sensitivity to targeted therapy. Other types of specific therapies targeting alternative pathways 
of VEGF may be useful in treating these patients.  
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Table 1. Summary of the clinical, histological and immunohistochemical characteristics 
of the 98 patients and those with 0-1 VHL events. 
The histological prognostic factors were assessed for each tumor. Pathological diagnosis is 
according to Fuhrman’s grading system and UICC tumor-node-metastasis staging system. 
Values are presented as median (minimum – maximum) for continuous variables and number 
of patients (percentage) for categorical variables. The immunoexpression of VEGF and CAIX 
were considered positive if the percentage of stained tumor cells was above a defined 
threshold of 30% and 85% respectively. The inflammatory extent was coded as 1 (sparse or 
rare lymphocytes around the tumor) or as 2 (marked dense lymphocytes or lymphoid 
nodules). 
 
Figure1. Results of the complete VHL gene status of the 98 ccRCC patients. 
VHL gene mutations are mutually exclusive to promoter hypermethylations.  
(n): number of events affecting the VHL gene. 
 
Table 2. Associations between VHL gene status and morphological parameters (Chi 2 
test) 
Activated VHL (0 or 1 event) tumors were significantly associated to metastases (p=0.043), 
higher Fuhrman grade 4 (p=0.02), sarcomatoid component (p=0.03), dense lymphocyte 
infiltrate (p=0.013) and VEGF overexpression (p=0.0001) compared to inactivated VHL 
tumors (2 events).  
** VEGF expression was an independent factor after multivariate analysis.  
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Figure 2. ccRCC pathological parameters associated with functional VHL gene (acVHL 
or wtVHL). 
A) ccRCC with Fuhrman grade 4 (x 40); 
B) ccRCC with sarcomatoid component (x 40); 
C) ccRCC with a dense lymphocyte infiltrate (x10); 
D) ccRCC with diffuse and strong cytoplasmic VEGF immunostaining (x 40).  
 
Figure 3. ccRCC specific survivals according to VHL gene status.  
inVHL (2) vs. [acVHL (1) & wtVHL (0)]: p=0.078 
wtVHL (0) vs. [inVHL(2) & acVHL(1)]: p=0.016 
wtVHL (0) vs. inVHL (2): p=0.009 
wtVHL : wild type VHL tumors with no alteration of the gene (0 event). acVHL : activated 
VHL tumors with one alteration of the gene (1 event). inVHL: inactivated VHL tumors with 2 
alterations of the gene (2 events).  
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